The first all-oral treatment for Trypanosoma brucei (T.b.) rhodesiense sleeping sickness, an acute form of the disease, is now available free of charge to patients in specialized treatment centres in Ethiopia, Malawi, Tanzania, Zambia, and Zimbabwe.
Ministries of Health in several African countries have approved the use of Fexinidazole Winthrop for T.b. rhodesiense sleeping sickness treatment.
‘Until now, the only treatment for the advanced stage of the disease involved a toxic intravenous drug that required hospitalization. Today, with this breakthrough, we have a safe and simple oral treatment that can be taken at home with minimal observation, revolutionizing care for patients. The authorization of Fexinidazole Winthrop in Malawi and several other African countries is a testament to the dedication and hard work of African doctors, clinicians, healthcare staff, and communities who contributed to its development,’ said Dr Westain Nyirenda, principal investigator of the clinical trials for Fexinidazole Winthrop in Malawi.
The clinical trials that led to Fexinidazole Winthrop’s approval were sponsored by the not-for-profit medical research organization Drugs for Neglected Diseases initiative (DNDi).
Sleeping sickness, or human African trypanosomiasis (HAT), is a parasitic disease transmitted by the bite of tsetse flies. It causes neuropsychiatric symptoms, including a debilitating disruption of sleep patterns and ultimately coma and death. It is almost always fatal if not treated. The T.b. rhodesiense form of the disease, which occurs in East and Southern Africa, progresses more rapidly than the T.b. gambiense form, which is endemic to Western and Central Africa.
Fexinidazole Winthrop was developed through an innovative partnership that brought together Sanofi, DNDi, national sleeping programmes, and local communities. The European Medicines Agency issued a positive scientific opinion for treatment of T.b. gambiense with Fexinidazole Winthrop in 2018. For T.b. rhodesiense sleeping sickness, DNDi led a Phase II/III clinical trial in Malawi and Uganda supported by a consortium of partners known as HAT-r-ACC that showed the treatment is a better alternative to existing drugs.
The results led the European Medicines Agency to issue a positive scientific opinion in December 2023. Following this decision, a regulatory approval was given in May 2025 by the regulatory authorities of the Democratic Republic of the Congo and subsequently, Malawi approved its use in December 2024. In June 2024, the World Health Organization (WHO) included it as the first-choice treatment for rhodesiense sleeping sickness in its treatment guidelines. Since the beginning of 2025, importation and distribution of the drug have been approved in the five African countries listed above and received shipments from WHO. Several patients have already received this life-saving treatment in Malawi, Zambia, and Zimbabwe.
Deadly outbreaks of rhodesiense sleeping sickness still occur, most recently in Malawi from 2019 to 2021. A localized rhodesiense outbreak in Ethiopia in 2022 – the first in 30 years – has been linked to climate and environmental changes that bring humans and animals such as cattle in closer proximity to the tsetse flies that carry the disease. Safari tourists from Europe and the US visiting the region have also fallen ill with this strain of sleeping sickness and have received Fexinidazole Winthrop under compassionate use protocols in Austria, Denmark, Poland, and the United States.
‘With climate and environmental changes increasing the risk of future rhodesiense outbreaks, we are now prepared to meet these challenges head-on with all-oral treatments, which will save lives and ease the burden on our healthcare systems in Africa,’ said Dr Junior Matangila, Head of DNDi’s sleeping sickness programme. ‘This is important, as it will be difficult to interrupt transmission of the rhodesiense form of sleeping sickness because it has an animal reservoir. On the other hand, as the reservoir of gambiense sleeping sickness is essentially human, interruption of transmission is an attainable goal. So far, eight countries have eliminated gambiense sleeping sickness as a public health problem, the latest being Guinea earlier this year.’
Fexinidazole Winthrop is recommended for adults and children aged six years or older and weighing at least 20 kg who have been diagnosed with either first-stage (haemolymphatic) or second-stage (meningoencephalitic) rhodesiense sleeping sickness in addition to the treatment of gambiense sleeping sickness approved in 2018. The all-oral treatment is donated to the WHO by Foundation S, Sanofi’s philanthropic organization, and delivered to Africa by the Médecins Sans Frontières Logistique supply centre.
‘We are thrilled to see the access and use of Fexinidazole Winthrop as the first fully oral treatment to treat rhodesiense sleeping sickness in Africa. This milestone underscores Sanofi’s unwavering long-term commitment to addressing neglected tropical diseases challenges and improving patient outcomes. Through Foundation S, we are dedicated to providing innovative treatments to those who need them most, ensuring that no patient is left behind. This approval is a testament to the power of collaboration and the impact we can achieve together, contributing further to eliminate sleeping sickness,’ said Philippe Neau, Head of the Neglected Tropical Diseases (NTDs) Programme at Foundation S, the Sanofi collective.
The DNDi clinical trial for T.b. rhodesiense sleeping sickness was conducted by the HAT-r-ACC Consortium, with funding from the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme supported by the European Union (through the grant RIA2017NCT-1846); Fundação para a Ciência e a Tecnologia, Portugal; the Swiss Agency for Development and Cooperation (SDC); Médecins Sans Frontières; UK International Development; and other private foundations and individuals.
About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected people. DNDi and its partners have developed three safe, effective, and accessible treatments for both forms of sleeping sickness, including the combination NECT in 2009; the first all-oral treatment Fexinidazole Winthrop for the gambiense form of sleeping sickness in 2018; and Fexinidazole Winthrop for the rhodesiense form of the disease in 2023. DNDi and Sanofi are also developing a promising, single-dose oral treatment for sleeping sickness called acoziborole that opens the door to the elimination of the disease in Africa. Since its creation in 2003, DNDi has joined with public and private partners across the globe to deliver 13 new treatments, saving millions of lives. dndi.org
About HAT-r-ACC
The HAT-r-ACC consortium brings together a broad range of partners with expertise in sleeping sickness and capacity building in remote healthcare settings. This research, training, and community engagement experience were essential to running the clinical trial in remote settings with a very small target population. The consortium partners include the Malawi Ministry of Health, the Uganda National Health Research Organisation, the Makerere University of Uganda, Epicentre (MSF) in France, the Lisbon Institute of Hygiene and Tropical Medicine in Portugal, the Institut de Recherche pour le Développement in France, the Swiss Tropical and Public Health Institute (Swiss TPH), and the WHO.
Media contacts
DNDi
Frédéric Ojardias (in Geneva)
+41 79 431 62 16
fojardias@dndi.org
Linet Otieno (in Nairobi)
+254 733 624 206
latieno@dndi.org
Photo credit: Thoko Chikondi-DNDi
